...
search icon
akba-img

Akebia Ther, Common Stock

AKBA

NAQ

$2.38

+$0.1

(4.39%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$540.75M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.26M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.86
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.8 L
$2.89 H
$2.38

About Akebia Ther, Common Stock

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAKBASectorS&P500
1-Week Return14.98%3.64%6.36%
1-Month Return22.05%-5.42%-5.32%
3-Month Return3.48%-6.89%-8.86%
6-Month Return49.69%-7.54%-5.61%
1-Year Return78.95%-1.81%8.61%
3-Year Return405.52%2.1%27.58%
5-Year Return-69.64%35.25%90.38%
10-Year Return-71.9%88.1%160.03%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue295.31M213.58M292.60M194.62M160.18M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":72.32,"profit":true},{"date":"2022-12-31","value":99.08,"profit":true},{"date":"2023-12-31","value":65.91,"profit":true},{"date":"2024-12-31","value":54.24,"profit":true}]
Cost of Revenue295.91M153.39M84.80M74.15M63.18M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":51.84,"profit":true},{"date":"2022-12-31","value":28.66,"profit":true},{"date":"2023-12-31","value":25.06,"profit":true},{"date":"2024-12-31","value":21.35,"profit":true}]
Gross Profit(601.00K)60.18M207.81M120.47M97.00M[{"date":"2020-12-31","value":-0.29,"profit":false},{"date":"2021-12-31","value":28.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":57.97,"profit":true},{"date":"2024-12-31","value":46.68,"profit":true}]
Gross Margin(0.20%)28.18%71.02%61.90%60.56%[{"date":"2020-12-31","value":-0.29,"profit":false},{"date":"2021-12-31","value":39.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.16,"profit":true},{"date":"2024-12-31","value":85.27,"profit":true}]
Operating Expenses375.84M325.50M270.99M166.73M147.47M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.61,"profit":true},{"date":"2022-12-31","value":72.1,"profit":true},{"date":"2023-12-31","value":44.36,"profit":true},{"date":"2024-12-31","value":39.24,"profit":true}]
Operating Income(376.44M)(265.32M)(63.18M)(46.26M)(50.47M)[{"date":"2020-12-31","value":-37644200000,"profit":false},{"date":"2021-12-31","value":-26531800000,"profit":false},{"date":"2022-12-31","value":-6318200000,"profit":false},{"date":"2023-12-31","value":-4625600000,"profit":false},{"date":"2024-12-31","value":-5047200000,"profit":false}]
Total Non-Operating Income/Expense(15.89M)(37.46M)(29.13M)(11.92M)(37.12M)[{"date":"2020-12-31","value":-1588600000,"profit":false},{"date":"2021-12-31","value":-3745800000,"profit":false},{"date":"2022-12-31","value":-2913400000,"profit":false},{"date":"2023-12-31","value":-1191900000,"profit":false},{"date":"2024-12-31","value":-3712300000,"profit":false}]
Pre-Tax Income(383.46M)(282.84M)(92.56M)(51.92M)(69.41M)[{"date":"2020-12-31","value":-38345700000,"profit":false},{"date":"2021-12-31","value":-28284000000,"profit":false},{"date":"2022-12-31","value":-9256200000,"profit":false},{"date":"2023-12-31","value":-5192500000,"profit":false},{"date":"2024-12-31","value":-6941000000,"profit":false}]
Income Taxes(33.59M)(37.97M)13.45M41.68M-[{"date":"2020-12-31","value":-80.59,"profit":false},{"date":"2021-12-31","value":-91.1,"profit":false},{"date":"2022-12-31","value":32.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(349.87M)(244.87M)(106.01M)(93.60M)-[{"date":"2020-12-31","value":-34986700000,"profit":false},{"date":"2021-12-31","value":-24487000000,"profit":false},{"date":"2022-12-31","value":-10600900000,"profit":false},{"date":"2023-12-31","value":-9360310500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(383.46M)(282.84M)(92.56M)(56.95M)(69.41M)[{"date":"2020-12-31","value":-38345700000,"profit":false},{"date":"2021-12-31","value":-28284000000,"profit":false},{"date":"2022-12-31","value":-9256200000,"profit":false},{"date":"2023-12-31","value":-5694600000,"profit":false},{"date":"2024-12-31","value":-6941000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(349.87M)(244.87M)(106.01M)(51.92M)(69.41M)[{"date":"2020-12-31","value":-34986700000,"profit":false},{"date":"2021-12-31","value":-24487000000,"profit":false},{"date":"2022-12-31","value":-10600900000,"profit":false},{"date":"2023-12-31","value":-5192500000,"profit":false},{"date":"2024-12-31","value":-6941000000,"profit":false}]
EPS (Diluted)(1.93)(1.70)(0.44)(0.28)(0.33)[{"date":"2020-12-31","value":-193,"profit":false},{"date":"2021-12-31","value":-170,"profit":false},{"date":"2022-12-31","value":-44,"profit":false},{"date":"2023-12-31","value":-27.68,"profit":false},{"date":"2024-12-31","value":-33,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AKBA
Cash Ratio 0.64
Current Ratio 1.41
Quick Ratio 1.21

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AKBA
ROA (LTM) -12.49%
ROE (LTM) -553.45%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AKBA
Debt Ratio Lower is generally better. Negative is bad. 1.22
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.22

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AKBA
Trailing PE NM
Forward PE NM
P/S (TTM) 3.72
P/B 4.12
Price/FCF NM
EV/R 3.69
EV/Ebitda 63.95
PEG NM

FAQs

What is Akebia Ther share price today?

Akebia Ther (AKBA) share price today is $2.38

Can Indians buy Akebia Ther shares?

Yes, Indians can buy shares of Akebia Ther (AKBA) on Vested. To buy Akebia Ther from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AKBA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Akebia Ther be purchased?

Yes, you can purchase fractional shares of Akebia Ther (AKBA) via the Vested app. You can start investing in Akebia Ther (AKBA) with a minimum investment of $1.

How to invest in Akebia Ther shares from India?

You can invest in shares of Akebia Ther (AKBA) via Vested in three simple steps:

  • Click on Sign Up or Invest in AKBA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Akebia Ther shares
What is Akebia Ther 52-week high and low stock price?

The 52-week high price of Akebia Ther (AKBA) is $2.89. The 52-week low price of Akebia Ther (AKBA) is $0.8.

What is Akebia Ther price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Akebia Ther (AKBA) is 4.12

What is the Market Cap of Akebia Ther?

The market capitalization of Akebia Ther (AKBA) is $540.75M

What is Akebia Ther’s stock symbol?

The stock symbol (or ticker) of Akebia Ther is AKBA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top